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Abstract
Background: Proteolysis of matrix components, in particular elastin, is a major contributing factor to the
development of lung diseases such as emphysema and chronic obstructive pulmonary disease (COPD). MMP-12
(macrophage elastase) is a protease known to be involved in the progression of lung disease. The relatively low
abundance of MMP-12 has precluded the development of quantitative assays that can accurately measure MMP-12
protein levels and activity across cohorts of healthy and diseased individuals.
Methods: Commercial antibodies were screened for performance in sandwich ELISA and capture FRET activity
assay formats. Precision, accuracy, sensitivity, dilution linearity, and spike recovery were evaluated using sputum
samples.
Results: Total protein and capture FRET activity assays were developed that were sensitive enough to detect MMP-
12 in 37 of 38 donor sputum samples. A comparison of results between the two assays shows that a majority of
sputum MMP-12 is in the active form. No differences were seen between normal, asthmatic, and COPD donors.
Conclusion: Sensitive and quantitative assays for both MMP-12 activity and total protein in human induced
sputum have been developed. These assays can be used to evaluate MMP-12 as a biomarker for lung disease, and
to monitor efficacy of potential therapeutic compounds.
Background
MMP-12, also know as macrophage elastase, is a mem-
ber of the matrix metalloproteinases. MMP-12 is synthe-
sized as a 55 kD precursor molecule which is then
processed into a 22 kD mature active form by serine
proteinases [1]. MMP-12 activity is regulated through a
balance of inhibitory interactions with the Tissue Inhibi-
tors of Metalloproteinases (TIMPs) and activating inter-
actions with proteases including other MMPs [2]. Active
MMP-12 has the capacity to degrade extracellular
matrix components, in particular elastin [3], and is
involved in matrix remodeling both in normal develop-
ment and during pathophysiological disease. Disruption
of the balance between MMP-12 and its endogenous
inhibitors can result in diseases such as emphysema and
COPD.
A role for MMP-12 in cigarette smoke induced
emphesyma has been demonstrated [4]. The mechanism
involves the induction of TNF-alpha release from
macrophages followed by endothelial cell activation,
neutrophil recruitment and secretion of matrix degrad-
ing proteases [5]. The resulting elastin fragments have
been shown to chemotactic for monocytes, resulting in
further recruitment and amplification of the inflamma-
tory cascade [6].
A protective role for MMP-12 inhibitors has been
postulated [7], but specific, sensitive assays for the
detection of MMP-12 in human induced sputum are
currently unavailable. A challenge to the development of
MMP-12 assays is the autocatalysis seen when MMP-12
is purified away from its natural inhibitors, the TIMPs.
To ascertain the value of MMP-12 as a biomarker, as
well as to monitor the efficacy of small molecule thera-
peutics targeting MMP-12 directly, we have developed
both an activity and total MMP-12 protein assay that * Correspondence: plapan@wyeth.com
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activity in human induced sputum.
Methods
Antibodies
A total MMP-12 ELISA was developed using the Den-
dritics (Lyon, France) antibody cat# DDX0284 as a cap-
ture antibody and cat # DDX0281 as a detection
antibody [8]. The capture antibody for the FRET assay,
cat# DDX0282, was also obtained from Dendritics.
Additional MMP-12 specific antibodies were tested from
Sigma (St. Louis, MO) cat# M0807, R&D Systems (Min-
neapolis, MN) cat# MAP 919 and MAB 917, Genway,
(San Diego, CA) cat# 15-288-066A, Genetex (Irvine,
CA) cat# GTX11613, Epitomics (Burlingame, CA) cat#
1906-1, Dendritics cat# DDX0280, Affinity Bioreagents
(Rockford, IL) cat# PA1-25216 and PY-10169, Abgent
(San Diego, CA) cat#AB6196a, Abcam (Cambridge, MA)
cat# ab38395, ab38910, ab38908, ab37718, ab11614,
ab11613, and ab0025.
Antibody conjugation
Conjugation of AP (alkaline phosphatase) to the detec-
tion antibody DDX0281 was accomplished via a stable
thioether linkage between maleimide coupled to AP and
a sulfhydryl group introduced onto the antibody. 60 μL
of AP (~ 1 mg, Biozyme AP cat# 1596AA2x, 18.59 mg/
ml, 111000 U/ml) was dialyzed against 500 mls of buffer
EDB (30 mM TEA, 3 M NaCl, 50 μMZ n C l 2,1m M
MgCl2 pH 7.6) at 2-8°C overnight. 600-700 ul (~ 0.5
mg) of the monoclonal antibody DDX0281 was dialyzed
against 500 mls of TSE pH 8.4 (100 mM TEA, 0.9 mM
EDTA, 100 mM NaCl). The protein concentration was
measured post dialysis.
AP was activated by incubation with a 38:1 molar
ratio of sSMCC (Pierce cat# 1B110605) for 40 minutes
at room temperature on rollers. Conversion of primary
amines on the antibody was accomplished by incubation
with a 300:1 molar ratio of 2-IminoThiolane (Pierce
cat# 1L114603). Both reactions were terminated by the
addition of excess glycine.
Desalting for both proteins was performed on by gel-
filtration on a 5 ml Hi Trap Desalt (G25) column on an
AKTA FPLC. The antibody was exchanged into the TSE
pH 7.3 buffer by the gel-filtration and the AP was run
with TSMZ pH 7.2 (100 mM TEA, 100 mM NaCl, 1
mM MgCl2,5 0μMZ n C l 2). Absorbance at 280 nm was
monitored and fractions corresponding to the excluded
protein were collected and pooled.
Fractions containing the antibody (~300 μg) and AP
(~600 μg) were pooled for an equivalent 2:1 molar ratio
of enzyme to antibody. The pool was incubated for 90
mins at room temperature and the reaction was stopped
with 40 μL of a 10 mg/ml maleimide solution.
The conjugate was concentrated in a Perbio 7 K con-
centrator following the manufacturer’s instructions,
including a water wash to remove glycerol from the
membrane. The final volume loaded on a HiTrap col-
umn was 700 μl and the conjugate was desalted into
TSMZ pH 7.2 at 5 ml/min collecting 500 μl fractions.
From the chromatogram monitored at 280 nm frac-
tions 5,6, and 7 were pooled. The yield was 1.5 ml of
conjugate solution, with an absorbance of 0.36 AU at
280 nm (~500 ug total). A volume of 50 μlw a s
removed and frozen for analysis before addition of an
equal volume of Surmodics Alk Phos Stabilzyme
reagent. The final solution containing 160 ug/ml con-
jugate was stored at 2-8°C.
FRET substrates
FRET 520 substrate III (cat# 60570-01, Anaspec, San
Jose CA, 0.1 mg peptide) was dissolved in 80 μL DMSO.
275 μL of the peptide/DMSO solution was brought to
11 mL with FRET assay Buffer (50 mM Hepes, 100 mM
NaCl, 5 mM CaCl2, 0.005% Brij-35, pH 7.4) for a final
concentration of 20 μM. Additional substrates tested
were FRET 520 substrate II (cat# 60569-01), IV (cat#
60571-01), V (cat# 60572-01), VII (cat# 60574-01), IX
(cat# 60576-01), XI (cat# 60578-01), XII (cat# 60579-
01), XIII (cat# 60580-01), XIV (cat# 60581-01), XV (cat#
60582-01), and XVI (cat# 60583-01) all purchased from
Anaspec, (San Jose CA).
MMP Protein
Recombinant Pro-MMP-12 residues 1 to 470 was sup-
plied by R&D Systems, (Minneapolis, MN) 20 μLt o t a l
volume at a concentration of 500 μg/mL. A volume of
180 μl TCNB buffer (50 mM Tris pH 7.5, 10 mM
CaCl2, 0.15 M NaCl, 0.05% Brij35) was added to create
a5 0μg/mL stock, which was then aliquoted into 2.5 μL
aliquots and stored at -80°C.
To prepare active MMP-12, full length Pro-MMP-12
was diluted in TCNB buffer to 50 μg/mL and allowed to
incubate for 24 hours at 37°C. The resultant autocata-
lyzed MMP-12 was aliquoted into 2.5 μLa l i q u o t sa n d
stored at -80°C.
Additional MMPs tested were MMP-1 (cat# 901-
MP-010), MMP-2 (cat# 902-MP-010), MMP-3 (cat#
513-MP-010), MMP-7 (cat# 907-MP-010), MMP-8
(cat# 908-MP-010), MMP-10 (cat# 910-MP-010),
MMP-13 (cat# 511-MM-010), MMP-14 (cat# 918-
MP-010) all supplied by R&D Systems. MMP-9 was
manufactured by Pfizer Research (Cambridge, MA).
MMP propeptides were diluted to 50 ug/mL in TCNB
buffer and treated with 1 mM APMA at 37°C for 2
hours for activation. MMP-14 was diluted to 40 ug/
mL and incubated with 0.86 μg/mL furin for 90 min-
utes at 37°C.
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For both the activity and total protein assays, to increase
inter-assay precision of the standard curve, standard
dilutions were batch prepared in advance and frozen in
aliquots.
To batch prepare prealiquoted standard curves for the
activity assay, an aliquot of autocatalyzed MMP-12 was
thawed and 2 μL added to 5 mL BlottoB (Rockland
Immunochemicals, Philadelphia, PA, cat# B553-0500) in
the first channel of a 12 channel pipette reservoir, pro-
ducing the first standard at 20,000 pg/mL. Seven addi-
tion channels are filled with 3 mL BlottoB. 1.5 mL of
the 20,000 pg/mL standard is three fold serially diluted
with 3 mL of BlottoB to produce six additional stan-
dards of 6,667, 2,222, 741, 247, 82, and 27 pg/mL, leav-
ing the eighth channel as the zero standard. A
multichannel pipettor is used to transfer 240 μLo fe a c h
standard into an eight tube PCR strip tube (VWR cat#
82006-606) with attached caps. Aliquots are stored fro-
zen at -80°C.
To batch prepare prealiquoted standard curves for the
MMP-12 total protein assay, an aliquot of full length
MMP-12 was thawed and 2 μL added to 400 μLP B S
0.05% Tween-20 (137 mM NaCl, 2.7 mM KCl, 10 mM
Sodium Phosphate dibasic, 2 mM Potassium Phosphate
monobasic, pH of 7.4) to create a 250 ng/mL stock. 38.4
μLo ft h e2 5 0n g / m Ls t o c kw a sa d d e dt o6m Lo f
ESD100 (CellTechnologies, Mountain View, CA, cat#
ESD100-2) supplemented with 50 μg/mL IIR (Immuno-
globulin Inhibiting Reagent, Bioreclamation Inc., West-
bury, NY. cat# 6LD1074) in the first channel of a 12
channel pipette reservoir, producing the first standard at
1,600 pg/mL. Seven additional channels are filled with 3
mL ESD100+IIR. 3 mL of the 1,600 pg/mL standard is
two fold serially diluted with 3 mL of ESD100+IIR to
produce six additional standards of 800, 400, 200, 100,
50, and 25 pg/mL, leaving the eighth channel as the
zero standard. A multichannel pipettor is used to trans-
fer 240 μL of each standard into an eight tube PCR strip
tube with attached caps. Aliquots are stored frozen at
-80°C.
Sample aquisition
Human sputum was collected by Analytical Biological
Services (Wilmington, DE) using a protocol originally
described by Pavord[9]. An ultrasonic nebuliser was
filled with 3% saline and subjects inhaled the nebulised
solution for 7 minutes following pre-treatment with
inhaled salbutamol. Next the nebuliser was filled with
4% saline and the nebulised solution is inhaled for 7
minutes. Finally, the nebuliser was filled with 5% saline
and the nebulised solution was inhaled for 7 minutes.
At 5-minute intervals the inhalation was stopped to
allow expectoration into a polypropylene container. A
total of four expectorations were collected and pooled.
The sample was kept on ice until centrifugation to har-
vest the soluble phase of sputum. The collection was
not performed on subjects with an FEV1 (Forced
Expiratory Volume in 1 second) <1 L.
Post collection, an equal volume of Buffer A (0.1%
DTT, 10% Sputolysin; 1 part Sputolysin and 9 parts nor-
mal saline) was added to the sputum sample. The sam-
ple was vortexed gently 3 times, and incubated in a
37°C water bath shaker for 15 minutes at 160 RPM.
Samples were mixed every 5 minutes during incubation
to ensure complete homogenization. Following incuba-
tion, samples were centrifuged at 1200 RPM for 10 min-
utes. Supernatant was removed and aliquoted into 150
μL aliquots before storage at -80°C. Reported concentra-
tions of MMP-12 were not adjusted for this two fold
dilution with Buffer A.
Automated plate washing
Plate washing was performed with a Biotek (Winooski,
VT) ELx405 96 channel plate washer. The standard
wash protocol involves five 300 μL washes, no soaking,
with a crosswise aspiration after the final wash. The
soak protocol involves five 300 μLw a s h e s ,w i t ha3 0
second soak for each wash followed by a crosswise
aspiration.
MMP-12 Total Protein ELISA protocol
1. Coat the capture antibody, Dendritics cat#
DDX0284, 1 hour at 3 μg/mL, 100 μL/well, 37°C in
ELISA coating buffer (0.1 M carbonate/bicarbonate
pH 9.55-9.65).
2. Wash with PBS wash buffer (137 mM NaCl, 2.7
mM KCl, 10 mM Sodium Phosphate dibasic, 2 mM
Potassium Phosphate monobasic, 0.05% Tween-20,
pH 7.4) at RT, standard wash program.
3. Block 1 hour with 200 μL/well Superblock (Pierce,
Rockford, IL cat# 37515), 37°C.
4. Wash with PBS wash buffer at RT, standard wash
program.
5. Add samples and standards in a total volume of
100 μL/well. Sputum samples are diluted 1:8 in
ESD100 (Cell Technology, Inc. Mountain View, CA)
supplemented with IIR (Immunoglobulin Inhibitory
Reagent cat# 6LD1074, Bioreclamation Inc., Hicks-
ville, NY); incubate overnight at 4°C.
6. Wash with Tris wash buffer (25 mM Tris pH 7.5,
150 mM NaCl, 0.05% Tween 20) at RT using the
soak program.
7. Add AP-DDX0281 conjugate detection antibody
at 100 ng/mL prepared in Tris wash buffer for
1 hour at RT.
8. Wash with Tris wash buffer at RT using the soak
program.
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Page 3 of 119. Use Invitrogen cat#19589-019 ELISA amplification
system. Reconstitute the substrate and amplifier with
12 mL of appropriate diluent 10 minutes at RT in
advance of use.
10. Add 50 μL per well of reconstituted substrate,
incubate 30 minutes at RT.
11. Add 50 μL per well of reconstituted amplifier in
the same sequence as the substrate. Incubate 30
minutes at RT.
12. Add 50 μL 2N sulfuric acid per well.
13. Read OD 495 nm at RT.
MMP-12-FRET activity assay
1. Dilute the capture antibody to 2 μg/mL in ELISA
coating buffer.
2. Add 100 μL per well to a NUNC Starwell plate
(Nunc, Roskilde, Denmark cat# 441653).
3. Seal and incubate at RT for 2 hours with
agitation.
4. Wash the plate on the ELx405 plate washer, stan-
dard wash program with PBS-0.05% Tween-20.
5. Add 250 μL per well of Superblock blocking
reagent.
6. Seal and incubate at RT for 2 hours with
agitation.
7. Wash the plate on the ELx405 using the standard
wash program with PBS-0.05% Tween-20.
8. Add 100 μL per well of standard or unknown
diluted in BlottoB.
9. Seal and incubate overnight at 4°C with agitation.
10. Reconstitute the FRET substrate. -Per tube of
substrate add 80 μL DMSO. -Dilute 275 μLo fs t o c k
substrate into 11 mL FRET Assay buffer
11. Wash the plate on the ELx405, standard wash
program with PBS-0.05% Tween-20.
12. Blot on paper towels. Apply a black plate sealer
(Perkin Elmer, Waltham, MA, cat# 6005189) to the
bottom of the Starwell plates.
13. Add 100 μL of substrate solution to each well.
Seal with a plate sealer.
14. Incubate the plate at RT for 24 hours with
agitation.
15. Remove the plate sealer and place into a fluores-
cent plate reader.
Read at room temperature, single endpoint, 1 second
integration per well, 0.5 second delay between wells,
excitation wavelength 485 nm, emission wavelength 527
nm, normal beam.
Data Analysis
Limits of quantitation are defined as the lowest and highest
standards that have both an intra- and inter-assay %CV
and %Bias of less than 20%. Dilution linearity is evaluated
by calculating the %bias of a sample that is serially diluted.
Two or more consecutive serial two fold dilutions exhibit-
ing a %bias less than 20% identify a range of linearity.
To evaluate intra-assay imprecision, three aliquots of
each sputum sample are run in duplicate per analytical
run. Mean and standard deviations are calculated for
each aliquot (N = 3). A total of three analytical runs are
performed to assess inter-assay imprecision. Mean and
standard deviation are calculated using plate averages
for each sputum sample (N = 3).
Curve fitting is performed using the five-parameter
logistic fit provided in SoftMax Pro v5.2 (Molecular
Devices, Sunnyvale, CA).
Results
MMP-12 Total ELISA development
An antibody pair originally identified by Demedts et al.
[8] was used in a sandwich format to detect total MMP-
12 in human induced sputum. In the original format,
antibody DDX0284 is used as a capture antibody and
biotinylated antibody DDX0281 is the detection anti-
body, followed by streptavidin-HRP. This format exhib-
ited poor dilution linearity and poor sensitivity, with
only 31 of 38 donor sputum samples above the lower
limit of quantitation (LLOQ) of 78 pg/mL when diluted
1:2 (data not shown). A screen of commercially available
diluents identified ESD-100 as a diluent that exhibited
good dilution linearity in the 1:4 to 1:8 dilution range.
Tetrazolium amplification combined with direct alkaline
phosphatase conjugation provided enhanced sensitivity,
which allowed for a 1:8 dilution of sputum samples.
G i v e na nL L O Qo f5 0p g / m La n da nU L O Qo f1 6 0 0
pg/mL, the reportable range of the assay is 400-12,800
pg/mL. Under these conditions 37 of 38 donor samples
were within the reportable range of the assay.
Calibration Curve Range
The mean intra-assay imprecision (%CV) and accuracy
(%Bias) from five (5) analytical runs for each of the seven
calibrators are shown in Additional file 1, Table S1. The
inter-assay imprecision (%CV) and accuracy (%Bias) of
the calibration curve is shown in Additional file 1, Table
S2. The LLOQ of the assay is 50 pg/mL at which concen-
tration the inter-assay %CV and %Bias were 7.7% and
-5.8%, respectively. The ULOQ of the assay was 1600 pg/
mL at which concentration the inter-assay %CV and %
Bias were 2.6% and -1.1%, respectively. A typical calibra-
tion curve is shown in Additional file 2, Figure S1.
Determination of Sample Minimum Required Dilution and
the Reportable Range
To determine the optimal dilution factor for human
induced sputum, samples were analyzed following a 1:2,
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Page 4 of 111:4, 1:8, or a 1:16 dilution in ESD100 diluent supple-
mented with 50 ug/mL IIR. Additional file 1, Table S3
shows that samples run at 1:2 through 1:16 reported
similar dilution corrected values, however at 1:16, one of
four samples was below LLOQ and at 1:2 one sample
was above the ULOQ. To minimize the possibility of
diluting samples below the LLOQ, samples are diluted
1:8 before analysis. Based on the LLOQ of 50 pg/mL
and the ULOQ of 1,600 pg/mL, the reportable range of
MMP-12 in human induced sputum is 400 to 12,800
pg/mL.
Donor Survey in the Presence and Absence of IIR
To determine the range of MMP-12 concentrations in
human induced sputum, and to determine the effect of
IIR, 38 induced sputum samples were collected from
asthma, COPD and normal donors (Additional file 1,
Table S4). Aliquots were analyzed in ESD100 diluent
supplemented with 50 μg/mL IIR or ESD100 without
IIR.
Results in Additional file 1, Table S5 show that the
percent difference in calculated MMP-12 concentrations
between samples with and without IIR ranged from
-139% to 92%, with 27 of 38 samples showing an abso-
lute difference greater than 25%. Intra-assay %CV with-
out IIR is 49.6%, and with IIR 4.1%. Given the beneficial
effect upon intra-assay reproducibility, and to reduce
the incidence of false positive signals due to human
anti-mouse antibodies, we decided to incorporate IIR
into the diluent at a final concentration of 50 μg/mL.
Sputum MMP-12 concentrations assayed in the pre-
s e n c eo fI I Rv a r i e df r o mo n es a m p l eb e l o wt h eL L O Q
to 12,294 pg/mL. The mean value of samples above the
LLOQ was 2967 pg/mL with and CV of 4.1% (Addi-
tional file 1, Table S5). Samples falling below the LLOQ
were not used in calculating mean or SD.
Analytical Performance: Intra- and Inter-assay Imprecision
of the QC Validation Samples
The overall performance of the assay was determined by
the intra- and inter-assay imprecision of the validation
samples analyzed in three analytical runs. Due to varia-
bility seen in two donors initially analyzed, a total of 10
donor samples ranging from 555 to 4154 pg/mL were
selected for analysis. The mean intra-assay imprecision
(%CV) for these validation samples ranged from 1 to
18% (Additional file 1, Table S6). The inter-assay impre-
cision (%CV) of the validation samples ranged from 10-
23% (Additional file 1, Table S7; n = 3 aliquots for each
validation sample analyzed in duplicate). Because none
of the endogenous QC validation samples were at the
high end of the standard curve, three aliquots of a
spike-in sample of 8,000 pg/mL were analyzed in three
different runs (Additional file 1, Table S8). The average
interpolated concentration for the QC high validation
sample was 6,487 pg/mL. Intra- and inter-assay preci-
sion of the QC high validation sample are 4.8% and
7.3% respectively.
Determination of Assay Accuracy and Recovery
MMP-12 protein from R&D Systems was spiked into
eighteen human sputum samples and into assay diluent
at three different concentrations (final theoretical spik-
ing concentrations of 800, 3200, and 8000 pg/mL). The
measured MMP-12 concentration in assay diluent
yielded the baseline comparison for recovery in sputum
(Additional file 1, Table S9). The actual spiked (nom-
inal) concentration of MMP-12 in sputum samples for
the theoretical spiking concentrations of 800, 3200, and
8000 pg/mL was 910, 3814, and 9217 pg/mL respec-
tively. The recovery ranged from 64% to 144% for the
high spike sample, 71% to 136% for the mid spike sam-
ple, and 81% to 130% for the low spike sample. 38 of 53
determinations were in the range of 75-125% recovery.
Sample Stability
Percent change from baseline (1 F/T) after freeze thaw
ranged from 31% to -10.7% (Additional file 1, Table
S10). All donors showed small changes from freeze thaw
to freeze thaw with the exception of donor 152, which
showed a large change between 1 (baseline) and 2 F/T,
and small changes (<5%) thereafter. These results sug-
gest that total MMP-12 is relatively stable to freeze
thaw cycles.
The stability of total MMP-12 in induced sputum
incubated at RT and 4°C for 2, 4, or 24 hours was evalu-
ated using four donor samples (Additional file 1, Table
S11). MMP-12 was stable in sputum with only 2 sam-
ples showing >25% change, both samples being 24 hour
room temperature samples.
It is suggested that samples should be thawed and
held at 4C for no more than 2 hours. Up to 4 freeze
thaw cycles have minimal impact on recovery of total
MMP-12.
MMP-12 FRET activity assay
A FRET activity assay makes use of a capture antibody
specific for the enzyme of interest coated onto a solid
substrate. When a biological sample is applied to the
coated antibody, enzyme is captured and other matrix
components are washed away. The amount of enzyme
captured is proportional to the concentration of the
enzyme in the biological fluid. The captured enzyme
then cleaves a supplied peptide which tethers a
quencher to a fluor, preventing fluorescence. When the
peptide is cleaved by the catalytic activity of the enzyme,
the fluor will be released from the quencher and fluor-
esce in proportion to the captured enzyme.
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Page 5 of 11MMP-12 is the least abundant of human MMP’si n
sputum, being present at 1/1000 fold the concentration
of the more abundant MMPs such as MMP-8 and
MMP-9 (data not shown). The specificity of an assay
that depended on the intersection of the specificity of
the antibody and the FRET peptide would not work for
MMP-12, given that any cross reactivity of the antibody
with other MMPs, in particular MMP-8 and MMP-9,
would saturate the capture antibody binding sites on the
plate and reduce sensitivity for MMP-12. We decided
that the specificity of the assay must be conferred by the
antibody, allowing for the use of a promiscuous FRET
peptide. Given this strategy, we screened a panel of anti-
bodies looking at the 24 hour endpoint signal (Figure 1)
using 20 μM Substrate V and 10 ng/mL mature MMP-
12. Antibodies were coated at either 1 or 10 μg/mL.
The highest signal was seen with antibodies from Den-
dritics (cat# DDX0282) Genway (cat# 15-288-066A) and
Abcam (cat# 11614). These antibodies were further
tested for specificity against a panel of mature MMPs.
The antibodies of interest were coated at their optimal
concentration, 10 μg/mL for Abcam 11614, and 1 μg/
mL for Dendritics 282 and Genway 066 as determined
from figure 1. Anaspec substrate III was used at a con-
centration of 20 uM. Analytes (Figure 2) were present at
1 μg/mL, except for 12a (autocatalyzed R&D Systems
MMP-12 at 1 ng/mL), 12 Wyeth cat (recombinant cata-
lytic MMP-12 at 10 ng/mL), 12 pro (Pro form MMP-12,
R&D Systems) and 12 autocat (autocatalyzed R&D Sys-
tems MMP-12) both at 10 ng/mL and n171, n168, two
sputum samples with unknown MMP-12
concentrations. The Dendritics antibody DDX0282 was
shown to produce the highest signal with mature MMP-
12 while showing no cross reactivity with other MMPs
(Figure 2).
In parallel, catalytic MMP-12 was tested against a
panel of FRET substrates. Substrate III provided the
greatest Vmax and was used in all subsequent assays
(Figure 3).
Calibration Curve Range
The mean intra-assay imprecision (%CV) and accuracy
(%Bias) from five (5) analytical runs for each of the
seven calibrators are shown in Additional file 1, Table
S12. The inter-assay imprecision (%CV) and accuracy (%
Bias) of the calibration curve is shown in Additional file
1, Table S13. The LLOQ of the assay was 82 pg/mL at
which concentration the inter-assay %CV and %Bias
were 9.4% and -16.7%, respectively. The ULOQ of the
assay was 20,000 pg/mL at which concentration the
inter-assay %CV and %Bias were 0.3% and -0.2%, respec-
tively. A typical calibration curve is shown in Additional
file 3, Figure S2.
Determination of Sample Minimum Required Dilution and
the Reportable Range
To determine the optimal dilution factor for human
induced sputum, samples were analyzed following a 1:2,
1:4, 1:8, or a 1:16 dilution in BlottoB. Additional file 1,
Table S14 shows that samples run at 1:2 through 1:16
reported similar values, however at 1:16, two of four
samples were below LLOQ. To minimize the possibility
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Figure 1 A comparison of commercially available MMP-12 antibodies as capture antibodies in the FRET activity assay format.
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Page 6 of 11of diluting samples below the LLOQ, samples are
diluted 1:2 before analysis. Based on the LLOQ of 82
pg/mL and the ULOQ of 20,000 pg/mL, the reportable
range of MMP-12 in human induced sputum is 164 to
40,000 pg/mL.
Donor Survey
To determine the range of MMP-12 concentrations in
human induced sputum, 38 induced sputum samples
were collected from asthma, COPD, and normal donors
(Additional file 1, Table S4). Sputum MMP-12 concen-
trations varied from below the LLOQ (1 donor) to 9,535
pg/mL (Additional file 1, Table S15). The mean value of
samples above the LLOQ was 1778 pg/mL for normal
donors, 2498 pg/mL for asthmatics, and 1298 for COPD
donors. The CVs were 9.0, 7.2, and 5.9 respectively.
Samples falling below the LLOQ were not used in calcu-
lating mean or SD.
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Page 7 of 11Analytical Performance: Intra- and Inter-assay Imprecision
of the QC Validation Samples
The overall performance of the assay was determined by
the intra- and inter-assay imprecision of the validation
samples analyzed in three (3) analytical runs. The mean
intra-assay imprecision (%CV) for Low, Mid, and High
validation samples was 19%, 14% and 4%, respectively
(Additional file 1, Table S16). The inter-assay impreci-
sion (%CV) of the validation samples was 11%, 8%, and
21% for Low, Mid, and High, respectively (n = 3 aliquots
for each validation sample analyzed in duplicate).
Determination of Assay Accuracy/Recovery
MMP-12 protein from R&D Systems was autocatalyzed
and spiked into four human sputum samples and into
assay diluent at three different concentrations (final the-
oretical spiking concentrations of 10,000, 3000, and
1000 pg/mL). The measured MMP-12 concentration in
assay diluent yielded the baseline comparison for recov-
ery in sputum (Additional file 1, Table S17). The actual
spiked (nominal) concentration of MMP-12 in sputum
samples for the theoretical concentrations of 10,000,
3,000, and 1000 pg/mL was 19,686, 5,828, and 1,786 pg/
mL respectively. The recovery ranged from 78.9% to
107.2% for the high spike sample, 83.3% to 99.9% for
the mid spike sample, and 86.5% to 107.5% for the low
spike sample.
Sample Stability
The stability of active MMP-12 in induced sputum incu-
bated at RT and 4°C for 2, 4, or 24 h was evaluated
using four donor samples (Additional file 1, Table S18).
MMP-12 was not stable in sputum with most samples
showing > 10% bias at all time points under both room
temperature and 4°C incubation. Changes between time
points were not always cumulative, indicating that some
of the differences seen were due to assay variability.
Neither time nor temperature showed an obvious trend.
It is suggested that samples should be thawed and held
at 4°C for no more than one hour prior to processing.
Percent change from baseline after freeze thaw ranged
from 23.7% to -30.7% (Additional file 1, Table S19).
Change from freeze thaw to freeze thaw were not cumu-
lative. Donors showed both increase and decrease in
MMP-12 concentration upon repeated freeze thaw. Due
to the lack of a consistent trend, it is recommended that
samples not be subjected to more than a total of 2
freeze thaw cycles.
Comparison of total protein and activity levels in healthy
and diseased donors
The MMP-12 total protein and activity assays were used
to assess total protein and activity levels in induced spu-
tum from 18 healthy, 10 asthma, and 10 COPD donors.
Figure 4 shows that interpolated concentrations for
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Figure 4 A pairwise plot of interpolated MMP-12 concentrations for both activity and total MMP-12 protein concentration in normal,
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Page 8 of 11MMP-12 are similar for both total protein and activity,
suggesting that a majority of the MMP-12 in sputum is
in the mature, active form. A comparison of MMP-12
levels across disease states (Figure 5) shows that the dif-
ferences do not reach significance at the p = 0.05 level
(Student’s t-test).
Discussion
Elastin is a major structural component of lung, and
elastin degradation is a contributing factor to lung dis-
eases such as emphysema and COPD. Elastin, the pri-
mary substrate for MMP-12, is digested at numerous
sites generating chemotactic matrikines [3,10]. Both
alveolar macrophages [11,12] and bronchial epithelial
cells [13,14] serve as pulmonary reservoirs of MMP-12,
the latter secreting MMP-12 in response to cigarette
smoke.
Evidence citing the involvement of MMP-12 in lung
disease is provided both by genetics [15,16] and by func-
tional inhibition of MMP-12 in animal models [17,18].
To investigate the efficacy of novel MMP-12 inhibitors
[19], sensitive, accurate assays that can measure MMP-
12 total protein and activity in biologically relevant
fluids such as sputum are needed.
In this report we describe two fully validated MMP-12
assays, one for the detection of total MMP-12 protein
and the second for the detection of MMP-12 activity in
human induced sputum. With these assays we have
measured total protein and activity in induced sputum
from both healthy and diseased (COPD, asthma) donors.
We find that the majority of MMP-12 present in spu-
t u mi si na c t i v ef o r m ,a n dw ed o n ’t see statistically sig-
nificant differences between healthy and diseased
individuals as previously reported by Demedts [8]. How-
ever our donor sample is small: 18 normal, 10 COPD,
and 10 asthma. In the Demedts COPD cohort, 7 of 28
(25%) of the individuals have MMP-12 protein levels
greater than twice the mean for that group. Our results
show a mean for the COPD cohort (1297.9 pg/mL)
below the mean for the normals (1778.2 pg/mL) with no
outliers amongst the COPD patients. Other factors such
as normalization methods and differences in sample col-
lection may also contribute to the differences we are
seeing with previously published data.
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Page 9 of 11We have screened a panel of ten different MMPs
against the peptide substrates shown in figure 3 and
found that all peptides are cleaved by at least three dif-
ferent MMPs, and eight of the peptides were cleaved by
more than five MMPs (data not shown). Specifically we
have found that MMP-9, which is 1000 fold more abun-
dant in sputum than MMP-12 (personal communica-
tion, A. Winkler, Pfizer Inflammation) will cleave all of
the peptides tested. Given the substrate promiscuity and
abundance of MMP-9 in human induced sputum, we
felt it was necessary to develop a capture FRET assay
where specificity is conferred by the capture antibody.
We would expect that a solution phase assay, without
the specificity of a capture antibody, would measure pri-
marily MMP-9 activity. Analogous to the total protein
assay, our capture FRET activity assay does not detect
elevated levels of MMP-12 activity in diseased donors,
as has been reported elsewhere [8].
Our current measurements of MMP-12 total protein
and activity are normalized to volume. We have experi-
mented with alternative normalization methods such as
total protein and cells counts, without seeing differences
in relative levels of MMP-12 levels or activity from
patient to patient. Studies are currently underway to
more thoroughly characterize MMP-12 levels in healthy
and diseased populations.
Conclusions
A total protein and an activity assay for the detection of
MMP-12 in human induced sputum have been devel-
oped. These assays show good specificity, sensitivity,
accuracy and precision and are suitable for the analysis
of clinical samples. A study involving 38 donor sputum
samples shows that the majority of MMP-12 present in
sputum is in the mature, active form.
Additional material
Additional file 1: Supporting tables. Data table S1 through S19.
Additional file 2: Figure S1. An example standard curve for the MMP-
12 total protein assay.
Additional file 3: Figure S2. An example standard curve for the MMP-
12 FRET activity assay.
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